KM
GYRE icon

Kalos Management’s Gyre Therapeutics GYRE Stock Holding History

Kalos Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,228
Closed -$58K – 285
2021
Q3 		$58K Sell
2,228
-93
-4% -$3.06K 0.02% 288
2021
Q2 		$74K Sell
2,321
-54
-2% -$1.85K 0.03% 259
2021
Q1 		$83K Hold
2,375
– – 0.03% 286
2020
Q4 		$112K Hold
2,375
– – 0.05% 237
2020
Q3 		$79K Sell
2,375
-66
-3% -$2.58K 0.04% 223
2020
Q2 		$107K Sell
2,441
-134
-5% -$6.29K 0.05% 204
2020
Q1 		$86K Buy
2,575
+134
+5% +$6.16K 0.04% 191
2019
Q4 		$121K Hold
2,441
– – 0.04% 188
2019
Q3 		$90K Buy
2,441
+133
+6% +$7.17K 0.04% 186
2019
Q2 		$127K Buy
2,308
+157
+7% +$9.81K 0.06% 180
2019
Q1 		$130K Sell
2,151
-290
-12% -$18.6K 0.08% 146
2018
Q4 		$147K Buy
2,441
+133
+6% +$9.81K 0.07% 173
2018
Q3 		$180K Buy
2,308
+1,175
+104% +$93.1K 0.1% 143
2018
Q2 		$244K Buy
+1,133
New +$199K 0.11% 167
2018
Q1 		– Sell
-1,613
Closed -$222K – 159
2017
Q4 		$222K Buy
+1,613
New +$82.3K 0.1% 187

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Kalos Management's GYRE Position: Q4 2021 in Review

Kalos Management sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 2,228 shares — an estimated $58K sold.

Kalos Management first reported a position in GYRE in Q4 2017 and held it in 15 quarters. The position peaked at $244K in Q2 2018. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

  • Kalos Management reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Kalos Management sold 2,228 Gyre Therapeutics shares in Q4 2021, an estimated $58K.
  • Kalos Management first reported a position in Gyre Therapeutics in Q4 2017 and held it in 15 quarters.
  • Kalos Management's Gyre Therapeutics position peaked at $244K in Q2 2018.
  • 51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on Kalos Management's 13F filing for Q4 2021, filed 3 Feb 2022.